» Articles » PMID: 17162189

Pathophysiology of Duchenne Muscular Dystrophy: Current Hypotheses

Overview
Journal Pediatr Neurol
Specialties Neurology
Pediatrics
Date 2006 Dec 13
PMID 17162189
Citations 200
Authors
Affiliations
Soon will be listed here.
Abstract

Duchenne muscular dystrophy is a devastating inherited neuromuscular disorder that affects one in 3300 live male births. Although the responsible gene and its product, dystrophin, have been characterized for more than 15 years, and a mouse model (mdx) has been developed, comprehensive understanding of the mechanism leading from the absence of dystrophin to the muscular degeneration is still debated. First, dystrophin is considered a key structural element in the muscle fiber, and the primary function of the dystrophin-associated protein complex is to stabilize plasma membrane, although a role of signaling is still possible. Mechanically induced damage through eccentric contractions puts a high stress on fragile membranes and provokes micro-lesions that could eventually lead to loss of calcium homeostasis, and cell death. Altered regeneration, inflammation, impaired vascular adaptation, and fibrosis are probably downstream events that take part in the muscular dystrophy and that probably vary a lot along species (i.e., mdx mice), probands within families, stressing the importance of epigenic factors. Because no etiologic therapy is available for Duchenne muscular dystrophy, a better understanding of the primary and downstream mechanisms could prove useful for producing new adjuvant treatments. All pathophysiologic mechanisms are reviewed together with perspectives on management.

Citing Articles

Early Cardiac Dysfunction in Duchenne Muscular Dystrophy: A Case Report and Literature Update.

Lupu M, Pintilie I, Teleanu R, Marin G, Vladacenco O, Severin E Int J Mol Sci. 2025; 26(4).

PMID: 40004149 PMC: 11855830. DOI: 10.3390/ijms26041685.


Quantitative Structure-Property Relationship Modeling with the Prediction of Physicochemical Properties of Some Novel Duchenne Muscular Dystrophy Drugs.

K J, Santiago R ACS Omega. 2025; 10(4):3640-3651.

PMID: 39926532 PMC: 11800030. DOI: 10.1021/acsomega.4c08572.


Sphingolipids mediate lipotoxicity in muscular dystrophies.

Wang Y, Shyh-Chang N Life Med. 2025; 1(3):273-275.

PMID: 39872745 PMC: 11749356. DOI: 10.1093/lifemedi/lnac015.


Serum metabolomic signatures of patients with rare neurogenetic diseases: an insight into potential biomarkers and treatment targets.

Wijekoon N, Gonawala L, Ratnayake P, Sirisena D, Gunasekara H, Dissanayake A Front Mol Neurosci. 2025; 17:1482999.

PMID: 39866907 PMC: 11759312. DOI: 10.3389/fnmol.2024.1482999.


Two Novel Mouse Models of Duchenne Muscular Dystrophy with Similar Dmd Exon 51 Frameshift Mutations and Varied Phenotype Severity.

Baikova I, Ilchuk L, Safonova P, Varlamova E, Okulova Y, Kubekina M Int J Mol Sci. 2025; 26(1).

PMID: 39796016 PMC: 11719507. DOI: 10.3390/ijms26010158.